Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10099065 | Journal of the American College of Radiology | 2005 | 10 Pages |
Abstract
The use of screening imaging technology such as electron beam computed tomography and computed tomographic scans for the early detection of coronary artery disease, lung cancer, and other diseases is rising, even though they have not been proven to reduce disease-specific mortality. Until randomized, controlled trials assess the efficacy of these tests as screening tests, they will remain controversial. It is unclear whether the potential benefits of these screening tests outweigh the risks. In a practice environment in which public demand and enthusiasm for screening is high, radiologists can recognize the ethical issues associated with unproven screening imaging tests; understand current national policies toward professionalism and informed and shared decision making for screening; draw on the lessons learned from the proliferation of another unproven screening test, the prostate-specific antigen blood test for prostate cancer; and work with others in the health care system to promote an ethical approach to screening imaging tests.
Related Topics
Health Sciences
Medicine and Dentistry
Radiology and Imaging
Authors
Evelyn C.Y. MD, MS,